Abstract
Effective non-genetic disease modifying treatments for Huntington’s disease (HD) will necessarily target multiple diverse neurodegenerative processes triggered by mutant huntingtin. Neurotrophin receptors are well-positioned for this task as they regulate signaling pathways that largely overlap with signaling networks contributing to HD-related synaptic dysfunction, glial activation, excitotoxicity, and other degenerative processes. This review will discuss the contributions of disrupted neurotrophin receptor-related signaling to primary HD neuropathologies, and prospects for harnessing this signaling to develop therapeutics to counteract HD degenerative mechanisms. Application of the native protein ligands has been challenging pharmacologically, but progress has been made with the advent of small molecule compounds that can selectively bind to and activate specific Trk receptors or p75NTR to promote trophic and/or inhibit degenerative signaling in cell populations preferentially affected in HD.
CNS & Neurological Disorders - Drug Targets
Title:Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease
Volume: 16 Issue: 3
Author(s): Danielle A. Simmons, Frank M. Longo and Stephen M. Massa*
Affiliation:
- Department of Neurology, San Francisco VAMC and UCSF, MS127, San Francisco, CA 94121,United States
Abstract: Effective non-genetic disease modifying treatments for Huntington’s disease (HD) will necessarily target multiple diverse neurodegenerative processes triggered by mutant huntingtin. Neurotrophin receptors are well-positioned for this task as they regulate signaling pathways that largely overlap with signaling networks contributing to HD-related synaptic dysfunction, glial activation, excitotoxicity, and other degenerative processes. This review will discuss the contributions of disrupted neurotrophin receptor-related signaling to primary HD neuropathologies, and prospects for harnessing this signaling to develop therapeutics to counteract HD degenerative mechanisms. Application of the native protein ligands has been challenging pharmacologically, but progress has been made with the advent of small molecule compounds that can selectively bind to and activate specific Trk receptors or p75NTR to promote trophic and/or inhibit degenerative signaling in cell populations preferentially affected in HD.
Export Options
About this article
Cite this article as:
Simmons A. Danielle, Longo M. Frank and Massa M. Stephen*, Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease, CNS & Neurological Disorders - Drug Targets 2017; 16 (3) . https://dx.doi.org/10.2174/1871527315666161107093047
DOI https://dx.doi.org/10.2174/1871527315666161107093047 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry The Role of Spiritual Health Experience with Intensity and Duration of Labor Pain While Childbearing and Postpartum
Current Women`s Health Reviews Vagus nerve stimulation in treating depression: A tale of two stories.
Current Molecular Medicine Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences Editorial (Thematic Issue: Role of Antioxidants Treatments on Oxidative Stress and Calcium Entry in Neurological Disease: Focus on TRP Channels)
Current Neuropharmacology Carbonic Anhydrase Inhibitors as Anticonvulsant Agents
Current Topics in Medicinal Chemistry GABAergic Drugs for the Treatment of Migraine
CNS & Neurological Disorders - Drug Targets Synthesis and Anticonvulsant Activity of N-(trans)- 3-phenylprop-2-en-1-yl (Cinnamyl) Derivatives of Aminoalkanols
Letters in Drug Design & Discovery Adenosine and ATP Receptors in the Brain
Current Topics in Medicinal Chemistry Bioinformatic Screening of Autoimmune Disease Genes and Protein Structure Prediction with FAMS for Drug Discovery
Protein & Peptide Letters Brain-Derived Neurotrophic Factor and Antidepressant Activity
Current Pharmaceutical Design Melatonin, its Metabolites and its Synthetic Analogs as Multi-Faceted Compounds: Antioxidant, Prooxidant and Inhibitor of Bioactivation Reactions
Current Medicinal Chemistry Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Current Pharmaceutical Design Multiple Roles for Glycogen Synthase Kinase-3 as a Drug Target in Alzheimers Disease
Current Drug Targets Impact of Dietary Fats on Brain Functions
Current Neuropharmacology Relationships Between Mitochondria and Neuroinflammation: Implications for Alzheimer’s Disease
Current Topics in Medicinal Chemistry Glioma Dynamics and Computational Models: A Review of Segmentation, Registration, and In Silico Growth Algorithms and their Clinical Applications
Current Medical Imaging Therapeutic Potential of Hepatocyte Growth Factor for Treating Neurological Diseases
Current Drug Therapy Status Epilepticus: An Overview
Current Drug Metabolism MtDNA As a Cancer Marker: A Finally Closed Chapter?
Current Genomics